Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 27th of January due to the national public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00409188
Registration number
NCT00409188
Ethics application status
Date submitted
7/12/2006
Date registered
8/12/2006
Date last updated
20/11/2015
Titles & IDs
Public title
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Query!
Scientific title
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Query!
Secondary ID [1]
0
0
EMR 63325-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
START
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Tecemotide (L-BLP25)
Treatment: Drugs - Single low dose cyclophosphamide
Treatment: Drugs - Placebo
Experimental: Tecemotide (L-BLP25) -
Placebo comparator: Placebo -
Treatment: Other: Tecemotide (L-BLP25)
After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
Treatment: Drugs: Single low dose cyclophosphamide
A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
Treatment: Drugs: Placebo
A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival time was defined as the time from randomization to death. Participants without events were censored at the last date they were known to be alive or the clinical cut-off date, whatever was earlier.
Query!
Timepoint [1]
0
0
Up to 66 months
Query!
Secondary outcome [1]
0
0
Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)
Query!
Assessment method [1]
0
0
Time to symptom progression (TTSP) was measured by LCSS. Symptomatic progression was defined as an increase (worsening) of the Average Symptomatic Burden Index (ASBI that is, the mean of the six major lung cancer specific symptom scores of the LCSS patient scale - ranging from 0 to 100 where higher score indicates worst outcome). Worsening was defined as a 10% increase in the scale breadth from the baseline score. TTSP is defined as the time from randomization to worsening in ASBI. Participants without event are censored at the date of the last LCSS assessment.
Query!
Timepoint [1]
0
0
Up to 66 months
Query!
Secondary outcome [2]
0
0
Time To Progression (TTP)
Query!
Assessment method [2]
0
0
Time from randomization to disease progression. Disease progression was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 \[RECIST v1.0\]) as at least a 20% increase in the sum of the longest diameter of target lesions from nadir, or the appearance of one or more new lesions.
Query!
Timepoint [2]
0
0
Up to 66 months
Query!
Secondary outcome [3]
0
0
One-, Two- and Three-year Survival Rate
Query!
Assessment method [3]
0
0
The percentages of participants who were alive at 1, 2, and 3 years were calculated as a cumulative percentage by Kaplan-Meier survival analysis approach.
Query!
Timepoint [3]
0
0
Years 1, 2, and 3
Query!
Secondary outcome [4]
0
0
Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions
Query!
Assessment method [4]
0
0
Treatment -emergent adverse events were defined as those with onset or worsening occurring at or after the first dosing day of study medication and up to 42 days after the last administration of any study drug or the clinical cut-off date. Injection site reactions were reported as assessed by the Investigator.
Query!
Timepoint [4]
0
0
From first dose up to 42 days after the last dose of the trial treatment
Query!
Eligibility
Key inclusion criteria
* Histologically or cytologically documented unresectable stage III non-small cell lung cancer (NSCLC)
* Documented stable disease or objective response, according to Response Evaluation Criteria in Solid Tumors (RECIST), after primary chemoradiotherapy (either sequential or concomitant) for unresectable stage III disease, within 4 weeks (28 days) prior to randomization
* Receipt of concomitant or sequential chemoradiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of >=50 Gray (Gy). Subjects must have completed the primary thoracic chemo-radiotherapy at least four weeks (28 days) and no later than 12 weeks (84 days) prior to randomization. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible
* Geographically accessible for ongoing follow-up, and committed to comply with the designated visits
* An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* A platelet count > 140 x 10^9/Liter; white blood cells (WBC) > 2.5 x 10^9/Liter and hemoglobin > 90 gram per liter (g/L)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Pre-Therapies:
* Undergone lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy
* Receipt of immunotherapy (e.g. interferons, tumor necrosis factor [TNF], interleukins, or biological response modifiers [granulocyte macrophage colony stimulating factor {GM-CSF}, granulocyte colony stimulating factor {G-CSF}, macrophage-colony stimulating factor {M-CSF}], monoclonal antibodies) within 4 weeks (28 days) prior to randomization
* Receipt of investigational systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to randomization
Disease Status:
* Metastatic disease
* Malignant pleural effusion at initial diagnosis and/or at study entry
* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
* Autoimmune disease
* A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies
* Any preexisting medical condition requiring chronic steroid or immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are allowed)
* Known Hepatitis B and/or C
Physiological Functions:
* Clinically significant hepatic dysfunction
* Clinically significant renal dysfunction
* Clinically significant cardiac disease
* Splenectomy
* Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response
Standard Safety:
* Pregnant or breast-feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator
* Known drug abuse/alcohol abuse
* Legal incapacity or limited legal capacity
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1513
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
0
0
Research Site - Nedlands
Query!
Recruitment hospital [2]
0
0
Research Site - Bankstown, NSW
Query!
Recruitment hospital [3]
0
0
Research Site - Camperdown
Query!
Recruitment hospital [4]
0
0
Research Site - Heidelberg
Query!
Recruitment hospital [5]
0
0
Research Site - Kingswood
Query!
Recruitment hospital [6]
0
0
Research Site - Saint Leonards
Query!
Recruitment hospital [7]
0
0
Research Site - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
- Nedlands
Query!
Recruitment postcode(s) [2]
0
0
- Bankstown, NSW
Query!
Recruitment postcode(s) [3]
0
0
- Camperdown
Query!
Recruitment postcode(s) [4]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
- Kingswood
Query!
Recruitment postcode(s) [6]
0
0
- Saint Leonards
Query!
Recruitment postcode(s) [7]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oklahoma
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oregon
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Pennsylvania
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
West Virginia
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Buenos Aires
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Santa Fe
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Cordoba
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Tandil
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Styria
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Upper Austria
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Inssbruck
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Salzburg
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Wein, Venna
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Wels
Query!
Country [36]
0
0
Austria
Query!
State/province [36]
0
0
Wien
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Brasschaat
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Brussels
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Haine-Saint Paul
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Leuven
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Liege
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Mechelen
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Bahia
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
De ao Paulo
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Minas Gerais
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Rio Grande Do Sol
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Rio Grande Do Sul
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Sao Paulo
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Ondina-Salvdor
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
Rio de Janeriro
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Alberta
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
British Columbia
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Manitoba
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Nova Scotia
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Ontario
Query!
Country [56]
0
0
Canada
Query!
State/province [56]
0
0
Quebec
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Beijing
Query!
Country [58]
0
0
China
Query!
State/province [58]
0
0
Guangzhou
Query!
Country [59]
0
0
China
Query!
State/province [59]
0
0
Shanghai
Query!
Country [60]
0
0
Czech Republic
Query!
State/province [60]
0
0
Hradec Králové
Query!
Country [61]
0
0
Czech Republic
Query!
State/province [61]
0
0
Ostrava-Poruba
Query!
Country [62]
0
0
Czech Republic
Query!
State/province [62]
0
0
Prague
Query!
Country [63]
0
0
Czech Republic
Query!
State/province [63]
0
0
Praha 2
Query!
Country [64]
0
0
Czech Republic
Query!
State/province [64]
0
0
Praha
Query!
Country [65]
0
0
Czech Republic
Query!
State/province [65]
0
0
Usti nad Labem
Query!
Country [66]
0
0
Denmark
Query!
State/province [66]
0
0
Herlev
Query!
Country [67]
0
0
Denmark
Query!
State/province [67]
0
0
Odense C
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Franche-Comte
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Rhone-Alpes
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Beuvry
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Brest
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Caen
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Chauny
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Marseille Cedex
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Marseille
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Nancy
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Nantes-Saint Herblain
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Paris Cedex 15
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Perpignan
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Poitiers Cedex
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Strasbourg Cedex
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Nordrhein-Westfalen
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Rheinland-Pfalz
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Saar
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Berlin
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Coswig
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Essen
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Frankfurt am Main
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Freiburg
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Gauting
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Großhansdorf
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Hamburg
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Heidelberg
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Kassel
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Kiel
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Koln
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Leipzig
Query!
Country [98]
0
0
Germany
Query!
State/province [98]
0
0
Magdeburg
Query!
Country [99]
0
0
Germany
Query!
State/province [99]
0
0
Mainz
Query!
Country [100]
0
0
Germany
Query!
State/province [100]
0
0
Minden
Query!
Country [101]
0
0
Germany
Query!
State/province [101]
0
0
Muchen
Query!
Country [102]
0
0
Germany
Query!
State/province [102]
0
0
München
Query!
Country [103]
0
0
Germany
Query!
State/province [103]
0
0
Oldenburg
Query!
Country [104]
0
0
Germany
Query!
State/province [104]
0
0
Rostock
Query!
Country [105]
0
0
Greece
Query!
State/province [105]
0
0
Athens
Query!
Country [106]
0
0
Greece
Query!
State/province [106]
0
0
Attica
Query!
Country [107]
0
0
Greece
Query!
State/province [107]
0
0
Nea Efkarpia
Query!
Country [108]
0
0
Greece
Query!
State/province [108]
0
0
Chidari, Athens
Query!
Country [109]
0
0
Greece
Query!
State/province [109]
0
0
Heraklion
Query!
Country [110]
0
0
Hong Kong
Query!
State/province [110]
0
0
New Territories
Query!
Country [111]
0
0
Hong Kong
Query!
State/province [111]
0
0
Hong Kong
Query!
Country [112]
0
0
Hungary
Query!
State/province [112]
0
0
Budapest
Query!
Country [113]
0
0
Hungary
Query!
State/province [113]
0
0
Mátraháza
Query!
Country [114]
0
0
Hungary
Query!
State/province [114]
0
0
Nyíregyháza
Query!
Country [115]
0
0
Hungary
Query!
State/province [115]
0
0
Tatabayana
Query!
Country [116]
0
0
India
Query!
State/province [116]
0
0
Chennai
Query!
Country [117]
0
0
India
Query!
State/province [117]
0
0
Hyderabad
Query!
Country [118]
0
0
India
Query!
State/province [118]
0
0
Mumbai
Query!
Country [119]
0
0
India
Query!
State/province [119]
0
0
New Delhi
Query!
Country [120]
0
0
India
Query!
State/province [120]
0
0
Vellore
Query!
Country [121]
0
0
Ireland
Query!
State/province [121]
0
0
Dublin
Query!
Country [122]
0
0
Israel
Query!
State/province [122]
0
0
Tel Avir
Query!
Country [123]
0
0
Israel
Query!
State/province [123]
0
0
Beer Sheva
Query!
Country [124]
0
0
Israel
Query!
State/province [124]
0
0
Haifa
Query!
Country [125]
0
0
Israel
Query!
State/province [125]
0
0
Jerusalem
Query!
Country [126]
0
0
Israel
Query!
State/province [126]
0
0
Kfar Saba
Query!
Country [127]
0
0
Israel
Query!
State/province [127]
0
0
Petach Tikva
Query!
Country [128]
0
0
Israel
Query!
State/province [128]
0
0
Tel Aviv
Query!
Country [129]
0
0
Israel
Query!
State/province [129]
0
0
Zerifin
Query!
Country [130]
0
0
Italy
Query!
State/province [130]
0
0
Torino
Query!
Country [131]
0
0
Italy
Query!
State/province [131]
0
0
Avelino
Query!
Country [132]
0
0
Italy
Query!
State/province [132]
0
0
Bologna
Query!
Country [133]
0
0
Italy
Query!
State/province [133]
0
0
Carpi
Query!
Country [134]
0
0
Italy
Query!
State/province [134]
0
0
Chieti
Query!
Country [135]
0
0
Italy
Query!
State/province [135]
0
0
Forli
Query!
Country [136]
0
0
Italy
Query!
State/province [136]
0
0
Genova
Query!
Country [137]
0
0
Italy
Query!
State/province [137]
0
0
Meldola
Query!
Country [138]
0
0
Italy
Query!
State/province [138]
0
0
Milano
Query!
Country [139]
0
0
Italy
Query!
State/province [139]
0
0
Napoli
Query!
Country [140]
0
0
Italy
Query!
State/province [140]
0
0
Orbassano-Torino
Query!
Country [141]
0
0
Italy
Query!
State/province [141]
0
0
Palermo
Query!
Country [142]
0
0
Italy
Query!
State/province [142]
0
0
Parma
Query!
Country [143]
0
0
Italy
Query!
State/province [143]
0
0
Rome
Query!
Country [144]
0
0
Italy
Query!
State/province [144]
0
0
Rozzano-Milano
Query!
Country [145]
0
0
Italy
Query!
State/province [145]
0
0
Sassari
Query!
Country [146]
0
0
Italy
Query!
State/province [146]
0
0
Trento
Query!
Country [147]
0
0
Korea, Republic of
Query!
State/province [147]
0
0
Gyeonggi-do
Query!
Country [148]
0
0
Korea, Republic of
Query!
State/province [148]
0
0
Gyeonggi-Do
Query!
Country [149]
0
0
Korea, Republic of
Query!
State/province [149]
0
0
Seoul
Query!
Country [150]
0
0
Mexico
Query!
State/province [150]
0
0
Michoacan
Query!
Country [151]
0
0
Mexico
Query!
State/province [151]
0
0
Chihuahua
Query!
Country [152]
0
0
Mexico
Query!
State/province [152]
0
0
Mexico City
Query!
Country [153]
0
0
Netherlands
Query!
State/province [153]
0
0
Noord-Holland
Query!
Country [154]
0
0
Netherlands
Query!
State/province [154]
0
0
Amsterdam
Query!
Country [155]
0
0
Netherlands
Query!
State/province [155]
0
0
Eindhoven
Query!
Country [156]
0
0
Netherlands
Query!
State/province [156]
0
0
Hoofdrop
Query!
Country [157]
0
0
Netherlands
Query!
State/province [157]
0
0
Tilburg
Query!
Country [158]
0
0
Netherlands
Query!
State/province [158]
0
0
Zwolle
Query!
Country [159]
0
0
Poland
Query!
State/province [159]
0
0
Mazowieckie
Query!
Country [160]
0
0
Poland
Query!
State/province [160]
0
0
Bialystok
Query!
Country [161]
0
0
Poland
Query!
State/province [161]
0
0
Bydgoszcz
Query!
Country [162]
0
0
Poland
Query!
State/province [162]
0
0
Bytom
Query!
Country [163]
0
0
Poland
Query!
State/province [163]
0
0
Gdynia
Query!
Country [164]
0
0
Poland
Query!
State/province [164]
0
0
Kraków
Query!
Country [165]
0
0
Poland
Query!
State/province [165]
0
0
Lodz
Query!
Country [166]
0
0
Poland
Query!
State/province [166]
0
0
Olsztyn
Query!
Country [167]
0
0
Poland
Query!
State/province [167]
0
0
Otwock
Query!
Country [168]
0
0
Poland
Query!
State/province [168]
0
0
Poznan
Query!
Country [169]
0
0
Poland
Query!
State/province [169]
0
0
Torun
Query!
Country [170]
0
0
Poland
Query!
State/province [170]
0
0
Warsaw
Query!
Country [171]
0
0
Poland
Query!
State/province [171]
0
0
Warszawa
Query!
Country [172]
0
0
Poland
Query!
State/province [172]
0
0
Wroclaw
Query!
Country [173]
0
0
Poland
Query!
State/province [173]
0
0
Zabrze
Query!
Country [174]
0
0
Portugal
Query!
State/province [174]
0
0
Coimbra
Query!
Country [175]
0
0
Portugal
Query!
State/province [175]
0
0
Lisboa
Query!
Country [176]
0
0
Portugal
Query!
State/province [176]
0
0
Porto
Query!
Country [177]
0
0
Portugal
Query!
State/province [177]
0
0
Santa Maria de Feira
Query!
Country [178]
0
0
Romania
Query!
State/province [178]
0
0
Bucharest
Query!
Country [179]
0
0
Romania
Query!
State/province [179]
0
0
Bucuresti
Query!
Country [180]
0
0
Romania
Query!
State/province [180]
0
0
Cluj-Napoca
Query!
Country [181]
0
0
Romania
Query!
State/province [181]
0
0
Iasi
Query!
Country [182]
0
0
Romania
Query!
State/province [182]
0
0
Sibiu
Query!
Country [183]
0
0
Romania
Query!
State/province [183]
0
0
Suceava
Query!
Country [184]
0
0
Romania
Query!
State/province [184]
0
0
Timisoara
Query!
Country [185]
0
0
Russian Federation
Query!
State/province [185]
0
0
Tatarstan
Query!
Country [186]
0
0
Russian Federation
Query!
State/province [186]
0
0
Yaroslavlr
Query!
Country [187]
0
0
Russian Federation
Query!
State/province [187]
0
0
Barnaul
Query!
Country [188]
0
0
Russian Federation
Query!
State/province [188]
0
0
Chelaybinsk
Query!
Country [189]
0
0
Russian Federation
Query!
State/province [189]
0
0
Ivanovo
Query!
Country [190]
0
0
Russian Federation
Query!
State/province [190]
0
0
Kazan
Query!
Country [191]
0
0
Russian Federation
Query!
State/province [191]
0
0
Moscow
Query!
Country [192]
0
0
Russian Federation
Query!
State/province [192]
0
0
Obninsk
Query!
Country [193]
0
0
Russian Federation
Query!
State/province [193]
0
0
Saint Petersburg
Query!
Country [194]
0
0
Russian Federation
Query!
State/province [194]
0
0
Tomsk
Query!
Country [195]
0
0
Russian Federation
Query!
State/province [195]
0
0
Voronezh
Query!
Country [196]
0
0
Singapore
Query!
State/province [196]
0
0
Singapore
Query!
Country [197]
0
0
Slovakia
Query!
State/province [197]
0
0
Bratislava
Query!
Country [198]
0
0
Slovakia
Query!
State/province [198]
0
0
Kosice
Query!
Country [199]
0
0
Slovakia
Query!
State/province [199]
0
0
Nitra
Query!
Country [200]
0
0
Spain
Query!
State/province [200]
0
0
Barcelona
Query!
Country [201]
0
0
Spain
Query!
State/province [201]
0
0
Bilbao
Query!
Country [202]
0
0
Spain
Query!
State/province [202]
0
0
Guipuzcoa
Query!
Country [203]
0
0
Spain
Query!
State/province [203]
0
0
A Coruna
Query!
Country [204]
0
0
Spain
Query!
State/province [204]
0
0
Alicante
Query!
Country [205]
0
0
Spain
Query!
State/province [205]
0
0
Burgos
Query!
Country [206]
0
0
Spain
Query!
State/province [206]
0
0
Girona
Query!
Country [207]
0
0
Spain
Query!
State/province [207]
0
0
Jaen
Query!
Country [208]
0
0
Spain
Query!
State/province [208]
0
0
Lugo
Query!
Country [209]
0
0
Spain
Query!
State/province [209]
0
0
Madrid
Query!
Country [210]
0
0
Spain
Query!
State/province [210]
0
0
Malaga
Query!
Country [211]
0
0
Sweden
Query!
State/province [211]
0
0
Gävle
Query!
Country [212]
0
0
Sweden
Query!
State/province [212]
0
0
Göteborg
Query!
Country [213]
0
0
Sweden
Query!
State/province [213]
0
0
Lund
Query!
Country [214]
0
0
Sweden
Query!
State/province [214]
0
0
Stockholm
Query!
Country [215]
0
0
Sweden
Query!
State/province [215]
0
0
Umea
Query!
Country [216]
0
0
Sweden
Query!
State/province [216]
0
0
Uppsala
Query!
Country [217]
0
0
Switzerland
Query!
State/province [217]
0
0
Basel
Query!
Country [218]
0
0
Switzerland
Query!
State/province [218]
0
0
Geneve
Query!
Country [219]
0
0
Switzerland
Query!
State/province [219]
0
0
Genève
Query!
Country [220]
0
0
Switzerland
Query!
State/province [220]
0
0
Winterthur
Query!
Country [221]
0
0
Taiwan
Query!
State/province [221]
0
0
Kaohsiung
Query!
Country [222]
0
0
Taiwan
Query!
State/province [222]
0
0
Taichung
Query!
Country [223]
0
0
Taiwan
Query!
State/province [223]
0
0
Tainan
Query!
Country [224]
0
0
Taiwan
Query!
State/province [224]
0
0
Taipei
Query!
Country [225]
0
0
Taiwan
Query!
State/province [225]
0
0
Tao-Yuan
Query!
Country [226]
0
0
United Kingdom
Query!
State/province [226]
0
0
Cornwall
Query!
Country [227]
0
0
United Kingdom
Query!
State/province [227]
0
0
Edinburgh
Query!
Country [228]
0
0
United Kingdom
Query!
State/province [228]
0
0
Glasgow
Query!
Country [229]
0
0
United Kingdom
Query!
State/province [229]
0
0
Guildford
Query!
Country [230]
0
0
United Kingdom
Query!
State/province [230]
0
0
Inverness
Query!
Country [231]
0
0
United Kingdom
Query!
State/province [231]
0
0
Leeds
Query!
Country [232]
0
0
United Kingdom
Query!
State/province [232]
0
0
Leicester
Query!
Country [233]
0
0
United Kingdom
Query!
State/province [233]
0
0
London
Query!
Country [234]
0
0
United Kingdom
Query!
State/province [234]
0
0
Manchester
Query!
Country [235]
0
0
United Kingdom
Query!
State/province [235]
0
0
Southampton
Query!
Country [236]
0
0
United Kingdom
Query!
State/province [236]
0
0
Surrey
Query!
Country [237]
0
0
United Kingdom
Query!
State/province [237]
0
0
Torquay
Query!
Country [238]
0
0
United Kingdom
Query!
State/province [238]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
EMD Serono
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Merck KGaA, Darmstadt, Germany
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00409188
Query!
Trial related presentations / publications
Butts C, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Helwig C, Falk MH, Shepherd FA. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. American Society of Clinical Oncology - 49th Annual Meeting. 2013; Abstr No. 7500. Shepherd FA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Helwig C, Schroeder A, Butts C. Updated analysis and secondary endpoints with L-BLP25 in unresectable stage III non-small cell lung cancer in the phase III START study. European Society for Medical Oncology 38th Congress - ECCO 17, ESMO 38, ESTRO 32. 2013. Abstr No. 3419. Mitchell P, Butts C, Socinski M, Thatcher N, Wichardt-Johansson G, Ellis P, Gladkov O, Pereira J, Eberhardt W, Horwood K, Szczesna A, Helwig C, Schröder A, Shepherd F. Tecemotide (L-BLP25) in unresectable stage III non-small cell lung cancer in the phase III START study: Further endpoint and exploratory biomarker results. World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2779. Thatcher N, Shepherd FA, Mitchell P, Socinski MA, Paredes A, Lambrechts M, Thomas M, Kollmeier J, Zemanová M, Sadjadian P, Peylan-Ramu N, Helwig C, Schröder A, Butts C. Geographic differences in the combined-modality treatment of stage III unresectable non-small cell lung cancer: Results from a global phase III trial of tecemotide (L-BLP25). World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2712. Socinski M, Butts C, Mitchell P, Thatcher N, Scagliotti G, Robinet G, Martin C, Zukin M, Ragulin Y, Bonomi P, Yang CH, Regnault A, Helwig C, de Nigris E, Shepherd F. Exploration of patient health status as measured by the generic preference-based questionnaire EQ-5D alongside the START trial of tecemotide in non-small cell lung cancer. World Conference on Lung Cancer - 15th. 2013; Abstr. No. 2744. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schroder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. DeGregorio M, Soe L, Wolf M. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis. 2014 Jun;6(6):571-3. doi: 10.3978/j.issn.2072-1439.2014.05.15. No abstract available. Zhu J, Yuan Y, Wan X, Yin D, Li R, Chen W, Suo C, Song H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub3. Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martin C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015 Jun;26(6):1134-1142. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Responsible
Query!
Address
0
0
EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Butts C, Socinski MA, Mitchell PL, Thatcher N, Hav...
[
More Details
]
Journal
DeGregorio M, Soe L, Wolf M. Tecemotide (L-BLP25) ...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00409188
Download to PDF